Posts: 7

Topic: Update on trial at NIH

I just returned home from my 4th checkup since my initial treatment in April on the GI-TIL trial at National Institute of Health. I have officially reached the partial response rate of 30.06% and am now considered a success and the first one to be successful!!!! I seem to be averaging about a 7% shrinkage rate on my tumors each month without any treatment other than the initial treatment in April. I feel amazing and am so happy this has been working! I just wanted to update with the news! God Bless...Melinda

Re: Update on trial at NIH

Melinda....fantastic news. Congratulations. Melinda, I am wondering: When initially reported, you mentioned that eight people had enrolled in this trial. http://www.ncbi.nlm.nih.gov/pubmed/19304471Out of these eight people, how many are treated for epithelial cancers? And, do you know whether other patients had also received prior chemotherapy?

Again, you deserve a big hug for the impressive response to the treatment of the immune system.

Thanks so much for sharing this important information with us.

Hugs,Marion

THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER

Re: Update on trial at NIH

Marion,

I am not sure of the exact types of GI cancers the eight before me had. All I know is that I am the first and so far the only Cholangio participant. I believe the others had received chemo, I think that is one of the requirements of the protocol. The trial information is listed at the following link and the protocol ID is 10016610-C-0166, NCT01174121 or you can search GI-TILhttp://www.cancer.gov/clinicaltrialsPlease let me know if you have any more questions.Melinda

The information expressed is not medical advice. The discussion boards are not intended to replace the services of a trained health professional or to be a substitute for the medical advice of physicians or other healthcare providers. Read the full disclaimer.